Perseus Proteomics Inc. (4882.T)

JPY 610.0

(-0.65%)

EBITDA Summary of Perseus Proteomics Inc.

  • Perseus Proteomics Inc.'s latest annual EBITDA in 2023 was -892 Million JPY , down -11.98% from previous year.
  • Perseus Proteomics Inc.'s latest quarterly EBITDA in 2024 Q1 was -221.25 Million JPY , down -6.38% from previous quarter.
  • Perseus Proteomics Inc. reported an annual EBITDA of -692 Million JPY in 2022, down -68.61% from previous year.
  • Perseus Proteomics Inc. reported an annual EBITDA of -471 Million JPY in 2021, up 13.81% from previous year.
  • Perseus Proteomics Inc. reported a quarterly EBITDA of -203.63 Million JPY for 2023 Q2, down -447.77% from previous quarter.
  • Perseus Proteomics Inc. reported a quarterly EBITDA of -37.17 Million JPY for 2023 Q1, up 83.03% from previous quarter.

Annual EBITDA Chart of Perseus Proteomics Inc. (2023 - 2019)

Historical Annual EBITDA of Perseus Proteomics Inc. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -892 Million JPY -11.98%
2022 -692 Million JPY -68.61%
2021 -471 Million JPY 13.81%
2020 -411.23 Million JPY -1366.12%
2019 -839.63 Million JPY 0.0%

Peer EBITDA Comparison of Perseus Proteomics Inc.

Name EBITDA EBITDA Difference
Kyowa Kirin Co., Ltd. 117.59 Billion JPY 100.759%
Astellas Pharma Inc. 195.34 Billion JPY 100.457%
Chugai Pharmaceutical Co., Ltd. 470.91 Billion JPY 100.189%
Ono Pharmaceutical Co., Ltd. 178.43 Billion JPY 100.5%
Santen Pharmaceutical Co., Ltd. 56.45 Billion JPY 101.58%
JCR Pharmaceuticals Co., Ltd. 10.72 Billion JPY 108.314%
Daiichi Sankyo Company, Limited 305.45 Billion JPY 100.292%
Otsuka Holdings Co., Ltd. 224.19 Billion JPY 100.398%